US OptionsDetailed Quotes
INMB250117P7500
- 3.00
- +0.70+30.43%
15min DelayTrading Dec 23 12:10 ET
3.00High3.00Low
3.00Open2.30Pre Close23 Volume21 Open Interest7.50Strike Price6.90KTurnover119.93%IV-1.15%PremiumJan 17, 2025Expiry Date3.05Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9338Delta0.1044Gamma1.48Leverage Ratio-0.0030Theta-0.0027Rho-1.38Eff Leverage0.0015Vega
INmune Bio Stock Discussion
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
1 MINUTE AGO, 3:03 PM EDT
VIA GLOBENEWSWIRE
INMB
SHARE
Data from Animal Model Study Demonstrate XPro™ converts microglia from a demyelinating cell to a remyelinating cell
Multi-year study published has implications for many CNS diseases including Alzheimer's
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
INmune Bio (NASDAQ: INMB) announces publication in Cell Reports demonstrating XPro™'s ability to promote remyelination in demyelinating disease animal models. The study, led by Dr. Leslie Probert at Hellenic Pasteur Institute, shows that XPro1595 converts microglia from damaging to reparative cells by blocking soluble TNF. This research has implications for treating various ...
• $SpringWorks Therapeutics (SWTX.US)$ +19.2% (Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase3DeFi Trial )
• $Roivant Sciences (ROIV.US)$ +7.1% (FDA has approved VTAMA (tapinarof) cream)
• $Ocugen (OCGN.US)$ +5.9% (announces that it is diversifying its innovative pipeline by introducing a Phase 3 cell therapy platform technology called Ne?Cart)
• $Champion Homes (SKY.US)$ +4.4% (In reaction to earnings）
• $NetEase (NTES.US)$ +4.1% (In...
No comment yet